A detailed history of Parkman Healthcare Partners LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Parkman Healthcare Partners LLC holds 1,087,634 shares of VRDN stock, worth $16.9 Million. This represents 3.03% of its overall portfolio holdings.

Number of Shares
1,087,634
Previous 425,000 155.91%
Holding current value
$16.9 Million
Previous $9.67 Million 115.65%
% of portfolio
3.03%
Previous 1.37%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$17.85 - $25.71 $11.8 Million - $17 Million
662,634 Added 155.91%
1,087,634 $20.8 Million
Q3 2024

Nov 14, 2024

BUY
$12.16 - $23.33 $5.17 Million - $9.92 Million
425,000 New
425,000 $9.67 Million
Q3 2022

Nov 14, 2022

BUY
$10.7 - $25.5 $378,330 - $901,629
35,358 New
35,358 $725,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $619M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Parkman Healthcare Partners LLC Portfolio

Follow Parkman Healthcare Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkman Healthcare Partners LLC with notifications on news.